Foster City, CA – According to filings with the U.S. Securities and Exchange Commission, SutroVax is raising $110,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Grant Pickering played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About SutroVax

SutroVax is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. SutroVax’s lead product candidate is a pneumococcal conjugate vaccine (PCV) that is designed to prevent invasive pneumococcal disease (IPD) caused by Streptococcus pneumoniae. SutroVax’s broad-spectrum PCV is designed to provide expanded protection against circulating strains of pneumococcus and has the potential to replace the current vaccines used in infants and adults.

To learn more about SutroVax, visit http://www.sutrovax.com/

Contact:
Grant Pickering, President and Chief Executive Officer
650-837-0111
gpickering@sutrovax.com
https://www.linkedin.com/in/grant-e-pickering-7a9b478/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved